Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Questran OTC switch for cholesterol lowering set for advisory committee review.

This article was originally published in The Tan Sheet

Executive Summary

BRISTOL-MYERS SQUIBB's QUESTRAN OTC SWITCH ADVISORY COMMITTEE REVIEW by FDA's Nonprescription Drugs and Endocrinologic & Metabolic Drugs Advisory Committees is set for Sept. 27. The committees will review data from Bristol-Myers Squibb's Rx-to-OTC switch NDAs for the cholestyramine products Questran and Questran Light (NDAs 16-640 and 19-669).
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS084219

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel